91 related articles for article (PubMed ID: 17597610)
1. The lack of effect of specific overexpression of IGF-1 in the central nervous system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model of ALS.
Messi ML; Clark HM; Prevette DM; Oppenheim RW; Delbono O
Exp Neurol; 2007 Sep; 207(1):52-63. PubMed ID: 17597610
[TBL] [Abstract][Full Text] [Related]
2. Expression of a pathogenic mutation of SOD1 sensitizes aprataxin-deficient cells and mice to oxidative stress and triggers hallmarks of premature ageing.
Carroll J; Page TK; Chiang SC; Kalmar B; Bode D; Greensmith L; Mckinnon PJ; Thorpe JR; Hafezparast M; El-Khamisy SF
Hum Mol Genet; 2015 Feb; 24(3):828-40. PubMed ID: 25274775
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor antagonism accelerates disease onset in the SOD1
McLeod VM; Lau CL; Chiam MDF; Rupasinghe TW; Roessner U; Djouma E; Boon WC; Turner BJ
Br J Pharmacol; 2019 Jul; 176(13):2111-2130. PubMed ID: 30849180
[TBL] [Abstract][Full Text] [Related]
4. Astrocyte-Mediated Neuromodulatory Regulation in Preclinical ALS: A Metadata Analysis.
Jordan K; Murphy J; Singh A; Mitchell CS
Front Cell Neurosci; 2018; 12():491. PubMed ID: 30618638
[TBL] [Abstract][Full Text] [Related]
5.
Eleftheriadou I; Manolaras I; Irvine EE; Dieringer M; Trabalza A; Mazarakis ND
Ann Clin Transl Neurol; 2016 Oct; 3(10):752-768. PubMed ID: 27752511
[TBL] [Abstract][Full Text] [Related]
6. The Paradoxical Signals of Two TrkC Receptor Isoforms Supports a Rationale for Novel Therapeutic Strategies in ALS.
Brahimi F; Maira M; Barcelona PF; Galan A; Aboulkassim T; Teske K; Rogers ML; Bertram L; Wang J; Yousefi M; Rush R; Fabian M; Cashman N; Saragovi HU
PLoS One; 2016; 11(10):e0162307. PubMed ID: 27695040
[TBL] [Abstract][Full Text] [Related]
7. Potential new complication in drug therapy development for amyotrophic lateral sclerosis.
Garbuzova-Davis S; Thomson A; Kurien C; Shytle RD; Sanberg PR
Expert Rev Neurother; 2016 Dec; 16(12):1397-1405. PubMed ID: 27362330
[TBL] [Abstract][Full Text] [Related]
8. Progressive impairment of CaV1.1 function in the skeletal muscle of mice expressing a mutant type 1 Cu/Zn superoxide dismutase (G93A) linked to amyotrophic lateral sclerosis.
Beqollari D; Romberg CF; Dobrowolny G; Martini M; Voss AA; Musarò A; Bannister RA
Skelet Muscle; 2016; 6():24. PubMed ID: 27340545
[TBL] [Abstract][Full Text] [Related]
9. The Role of Skeletal Muscle in Amyotrophic Lateral Sclerosis.
Loeffler JP; Picchiarelli G; Dupuis L; Gonzalez De Aguilar JL
Brain Pathol; 2016 Mar; 26(2):227-36. PubMed ID: 26780251
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Muscle Denervation in Aging: Insights from a Mouse Model of Amyotrophic Lateral Sclerosis.
Park KH
Aging Dis; 2015 Sep; 6(5):380-9. PubMed ID: 26425392
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.
Dupuis L; Dengler R; Heneka MT; Meyer T; Zierz S; Kassubek J; Fischer W; Steiner F; Lindauer E; Otto M; Dreyhaupt J; Grehl T; Hermann A; Winkler AS; Bogdahn U; Benecke R; Schrank B; Wessig C; Grosskreutz J; Ludolph AC;
PLoS One; 2012; 7(6):e37885. PubMed ID: 22715372
[TBL] [Abstract][Full Text] [Related]
12. Tetanus toxin C-fragment: the courier and the cure?
Toivonen JM; Oliván S; Osta R
Toxins (Basel); 2010 Nov; 2(11):2622-44. PubMed ID: 22069568
[TBL] [Abstract][Full Text] [Related]
13. Expression and regulation of excitation-contraction coupling proteins in aging skeletal muscle.
Delbono O
Curr Aging Sci; 2011 Dec; 4(3):248-59. PubMed ID: 21529320
[TBL] [Abstract][Full Text] [Related]
14. Motor neuron trophic factors: therapeutic use in ALS?
Gould TW; Oppenheim RW
Brain Res Rev; 2011 Jun; 67(1-2):1-39. PubMed ID: 20971133
[TBL] [Abstract][Full Text] [Related]
15. AAV4-mediated expression of IGF-1 and VEGF within cellular components of the ventricular system improves survival outcome in familial ALS mice.
Dodge JC; Treleaven CM; Fidler JA; Hester M; Haidet A; Handy C; Rao M; Eagle A; Matthews JC; Taksir TV; Cheng SH; Shihabuddin LS; Kaspar BK
Mol Ther; 2010 Dec; 18(12):2075-84. PubMed ID: 20859261
[TBL] [Abstract][Full Text] [Related]
16. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?
Henriques A; Pitzer C; Schneider A
Front Neurosci; 2010 Jun; 4():32. PubMed ID: 20592948
[TBL] [Abstract][Full Text] [Related]
17. Motor neuron-immune interactions: the vicious circle of ALS.
Barbeito AG; Mesci P; Boillée S
J Neural Transm (Vienna); 2010 Aug; 117(8):981-1000. PubMed ID: 20552235
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ; Windbank AJ; Mandrekar JN; Bamlet WR; Appel SH; Armon C; Barkhaus PE; Bosch P; Boylan K; David WS; Feldman E; Glass J; Gutmann L; Katz J; King W; Luciano CA; McCluskey LF; Nash S; Newman DS; Pascuzzi RM; Pioro E; Sams LJ; Scelsa S; Simpson EP; Subramony SH; Tiryaki E; Thornton CA
Neurology; 2008 Nov; 71(22):1770-5. PubMed ID: 19029516
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factors in the peripheral nervous system.
Sullivan KA; Kim B; Feldman EL
Endocrinology; 2008 Dec; 149(12):5963-71. PubMed ID: 18719018
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I for the treatment of amyotrophic lateral sclerosis.
Sakowski SA; Schuyler AD; Feldman EL
Amyotroph Lateral Scler; 2009 Apr; 10(2):63-73. PubMed ID: 18608100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
